BRPI0410563B8 - compostos de pirazol-quinazolina, seus processos de preparação e composições farmacêuticas - Google Patents

compostos de pirazol-quinazolina, seus processos de preparação e composições farmacêuticas

Info

Publication number
BRPI0410563B8
BRPI0410563B8 BRPI0410563A BRPI0410563A BRPI0410563B8 BR PI0410563 B8 BRPI0410563 B8 BR PI0410563B8 BR PI0410563 A BRPI0410563 A BR PI0410563A BR PI0410563 A BRPI0410563 A BR PI0410563A BR PI0410563 B8 BRPI0410563 B8 BR PI0410563B8
Authority
BR
Brazil
Prior art keywords
pyrazol
pharmaceutical compositions
preparation processes
quinazoline compounds
preparation
Prior art date
Application number
BRPI0410563A
Other languages
English (en)
Inventor
Panzeri Achille
Vulpetti Anna
Fancelli Daniele
Quartieri Francesca
Roletto Fulvia
Traquandi Gabriella
Gabriella Brasca Maria
Vianello Paola
Pevarello Paolo
Polucci Paolo
D'alessio Roberto
Ferguson Ron
Original Assignee
Nerviano Medical Sciences Srl
Pfizer Italia Srl
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33476970&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0410563(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nerviano Medical Sciences Srl, Pfizer Italia Srl, Pharmacia Italia Spa filed Critical Nerviano Medical Sciences Srl
Priority to BR122019010200A priority Critical patent/BR122019010200B8/pt
Publication of BRPI0410563A publication Critical patent/BRPI0410563A/pt
Publication of BRPI0410563B1 publication Critical patent/BRPI0410563B1/pt
Publication of BRPI0410563B8 publication Critical patent/BRPI0410563B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

derivados de pirazol-quinazolina, processo para sua preparação e seu uso como inibidores de quinase. a presente invenção refere-se aos derivados de pirazol- quinazolina de fórmula (ia) ou (ib) como definidos no relatório, e sais farmaceuticamente aceitáveis dos mesmos, processo para sua preparação e composições farmacêuticas compreendendo os mesmos são descritos, os compostos da invenção podem ser utilizáveis, em terapia, no tratamento de doenças associadas com uma atividade de proteína quinase desregulada, como câncer
BRPI0410563A 2003-05-22 2004-04-27 compostos de pirazol-quinazolina, seus processos de preparação e composições farmacêuticas BRPI0410563B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122019010200A BR122019010200B8 (pt) 2003-05-22 2004-04-27 compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47266103P 2003-05-22 2003-05-22
US60/472,661 2003-05-22
PCT/EP2004/050612 WO2004104007A1 (en) 2003-05-22 2004-04-27 Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors

Publications (3)

Publication Number Publication Date
BRPI0410563A BRPI0410563A (pt) 2006-06-20
BRPI0410563B1 BRPI0410563B1 (pt) 2020-12-01
BRPI0410563B8 true BRPI0410563B8 (pt) 2021-05-25

Family

ID=33476970

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122019010200A BR122019010200B8 (pt) 2003-05-22 2004-04-27 compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas
BRPI0410563A BRPI0410563B8 (pt) 2003-05-22 2004-04-27 compostos de pirazol-quinazolina, seus processos de preparação e composições farmacêuticas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122019010200A BR122019010200B8 (pt) 2003-05-22 2004-04-27 compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas

Country Status (36)

Country Link
US (8) US7482354B2 (pt)
EP (1) EP1636236B1 (pt)
JP (1) JP5043432B2 (pt)
KR (1) KR101084871B1 (pt)
CN (2) CN102079746A (pt)
AP (1) AP2064A (pt)
AR (2) AR044543A1 (pt)
AU (1) AU2004240772B2 (pt)
BR (2) BR122019010200B8 (pt)
CA (1) CA2526578C (pt)
CO (1) CO5721006A2 (pt)
CR (1) CR8102A (pt)
CY (1) CY1114708T1 (pt)
DK (1) DK1636236T3 (pt)
EA (1) EA010904B1 (pt)
EC (1) ECSP056194A (pt)
ES (1) ES2436524T3 (pt)
GE (1) GEP20094664B (pt)
HR (1) HRP20050967B8 (pt)
IL (1) IL172046A (pt)
IS (1) IS2939B (pt)
ME (1) ME00142B (pt)
MX (1) MXPA05012573A (pt)
MY (1) MY142019A (pt)
NO (1) NO334992B1 (pt)
NZ (1) NZ543661A (pt)
OA (1) OA13170A (pt)
PL (1) PL1636236T3 (pt)
PT (1) PT1636236E (pt)
RS (2) RS52899B (pt)
SI (1) SI1636236T1 (pt)
TN (1) TNSN05298A1 (pt)
TW (1) TWI349672B (pt)
UA (1) UA80763C2 (pt)
WO (1) WO2004104007A1 (pt)
ZA (1) ZA200509486B (pt)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA010904B1 (ru) * 2003-05-22 2008-12-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
US7772232B2 (en) 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
ITMI20041033A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Composti farmaceutici
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP5537035B2 (ja) 2006-02-10 2014-07-02 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Ｃｄｋ阻害剤、および成長因子抗体または抗有糸***剤を含む組合せ
KR20090007635A (ko) * 2006-05-09 2009-01-19 노파르티스 아게 철 킬레이터 및 항-신생물 약제를 포함하는 조합물 및 그의용도
WO2007149395A2 (en) * 2006-06-20 2007-12-27 Amphora Discovery Corporation 2,5-substituted oxazole derivatives as protein kinase inhibitors for the treatment of cancer
US7517882B2 (en) * 2006-09-18 2009-04-14 Polaris Group Protein kinase inhibitors
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
HUE024105T2 (hu) * 2006-12-21 2016-02-29 Nerviano Medical Sciences Srl Szubsztituált pirazolo-kinazolin származékok, eljárás azok elõállítására és kináz inhibitorként történõ alkalmazásuk
ZA200904912B (en) * 2006-12-21 2010-09-29 Nerviano Medical Sciences Srl Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
WO2009054332A1 (ja) 2007-10-23 2009-04-30 Banyu Pharmaceutical Co., Ltd. ピリドン置換ジヒドロピラゾロピリミジノン誘導体
US8841312B2 (en) 2007-12-19 2014-09-23 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
US8389533B2 (en) * 2008-04-07 2013-03-05 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
TWI426074B (zh) * 2008-04-30 2014-02-11 Nerviano Medical Sciences Srl ５－（２－胺基－嘧啶－４－基）－２－芳基－１ｈ－吡咯－３－羧醯胺之製造方法
CN102076689B (zh) * 2008-06-26 2014-10-15 内尔维阿诺医学科学有限公司 吡唑并-喹唑啉类
JP5579715B2 (ja) * 2008-07-29 2014-08-27 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ
CN102105151B (zh) * 2008-07-29 2013-12-18 内尔维阿诺医学科学有限公司 Cdk抑制剂在治疗神经胶质瘤中的应用
WO2010043676A1 (en) * 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (pi3-kinases) inhibitor
US8912194B2 (en) * 2008-11-24 2014-12-16 Nerviano Medical Sciences S.R.L. CDK inhibitor for the treatment of mesothelioma
IT1395724B1 (it) * 2009-02-25 2012-10-19 Neuroscienze Pharmaness S C A R L Composti farmaceutici
JP5650193B2 (ja) * 2009-03-20 2015-01-07 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 胸腺腫の治療のためのキナーゼ阻害剤の使用
WO2010122091A1 (en) 2009-04-22 2010-10-28 Boehringer Ingelheim International Gmbh Thia-triaza-as-indacenes as pi3-kinases inhibitors for the treatment of cancer
CN102428086B (zh) * 2009-04-29 2014-08-20 内尔维阿诺医学科学有限公司 Cdk抑制剂的盐类
AR076784A1 (es) * 2009-05-26 2011-07-06 Nerviano Medical Sciences Srl Combinacion terapeutica que comprende un inhibidor de plk1 y un agente antineoplasico
ES2553114T3 (es) * 2009-07-29 2015-12-04 Nerviano Medical Sciences S.R.L. Sales de inhibidor de plk
EP2528911B1 (en) * 2010-01-28 2017-10-25 President and Fellows of Harvard College Compositions and methods for enhancing proteasome activity
US8735386B2 (en) * 2010-07-23 2014-05-27 Boehringer Ingelheim International Gmbh Aminopyrazoloquinazolines
EP2598508B1 (en) 2010-07-30 2015-04-22 Nerviano Medical Sciences S.r.l. Isoxazolo-quinazolines as modulators of protein kinase activity
EP2619181A1 (en) 2010-09-23 2013-07-31 Syngenta Participations AG Novel microbiocides
RS55135B1 (sr) * 2010-10-25 2016-12-30 G1 Therapeutics Inc Cdk inhibitori
RU2652638C2 (ru) * 2010-12-17 2018-04-28 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Замещенные пиразолхиназолиновые производные в качестве ингибиторов киназы
JP5925808B2 (ja) * 2011-01-26 2016-05-25 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 三環式誘導体、これらの調製方法およびこれらのキナーゼ阻害剤としての使用
BR112013018515B1 (pt) * 2011-01-26 2021-06-29 Nerviano Medical Sciences S.R.I Derivados de pirrol tricíclico, processo para sua preparação e seu uso como inibidores da quinase
WO2012117021A2 (en) 2011-03-03 2012-09-07 Syngenta Participations Ag Novel microbiocidal oxime ethers
PT2937349T (pt) 2011-03-23 2017-03-24 Amgen Inc Inibidores duais tricíclicos fusionados de cdk 4/6 e flt3
EP3552664A1 (en) 2011-05-12 2019-10-16 Proteostasis Therapeutics, Inc. Proteostasis regulators
WO2013092460A1 (en) 2011-12-20 2013-06-27 Syngenta Participations Ag Cyclic bisoxime microbicides
TW201343648A (zh) 2012-01-23 2013-11-01 Boehringer Ingelheim Int 作為ｉｇｆ－１ｒ／ｉｒ抑制劑之新５，８－二氫－６ｈ－吡唑并［３，４－ｈ］喹唑啉
EP2641901A1 (en) 2012-03-22 2013-09-25 Syngenta Participations AG. Novel microbiocides
US9604980B2 (en) 2012-11-07 2017-03-28 Nerviano Medical Sciences S.R.L. Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
CN108283644B (zh) 2013-03-15 2022-03-18 G1治疗公司 在化学疗法期间对正常细胞的瞬时保护
US20140271460A1 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Highly Active Anti-Neoplastic and Anti-Proliferative Agents
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
AU2015243694B2 (en) 2014-04-07 2019-01-17 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido(4,5-e)indolizines
WO2015161283A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation
ES2873959T3 (es) 2014-05-28 2021-11-04 Piramal Entpr Ltd Combinación farmacéutica que comprende un inhibidor de CDK y un inhibidor de tiorredoxina reductasa para el tratamiento del cáncer
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
MX2018000657A (es) 2015-07-17 2018-09-06 Pasteur Institut Agente estimulador del receptor 5-hidroxi triptamina 1b para usarse como un promotor de la autorrenovación y/o diferenciación de células satélite.
CN110022869A (zh) 2016-07-15 2019-07-16 巴斯德研究院 用于皮肤和/或毛发修复的5-羟色胺1b受体刺激剂
CN108699067B (zh) * 2016-11-11 2021-06-15 上海海雁医药科技有限公司 吡啶胺取代的杂三环化合物、其制法与医药上的用途
CN110997678B (zh) * 2017-07-11 2023-02-21 内尔维亚诺医疗科学公司 作为胆碱激酶抑制剂的吡唑并喹唑啉衍生物
CN107383019B (zh) * 2017-07-28 2019-10-15 江苏艾凡生物医药有限公司 吡唑并[4,3-h]喹唑啉类化合物及其用途
ES2923415T3 (es) 2017-08-11 2022-09-27 Shengke Pharmaceuticals Jiangsu Ltd Compuesto de 1H-pirazolo[4,3-H]quinazolina que sirve como inhibidor de proteína quinasa
WO2021043190A1 (zh) * 2019-09-05 2021-03-11 成都赛诺希亚生物科技有限公司 异噁唑并[5,4-h]喹唑啉类化合物作为蛋白激酶抑制剂
WO2021084541A1 (en) * 2019-10-31 2021-05-06 Sol-Gel Technologies Ltd. Treatment of hair loss disorders with a topical egfr inhibitor
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
CN114685520A (zh) * 2020-12-25 2022-07-01 武汉誉祥医药科技有限公司 三并环化合物及其药物组合物和应用
CN116528871A (zh) * 2020-12-31 2023-08-01 恒元生物医药科技(苏州)有限公司 一种吡唑并喹唑啉类化合物、其制备方法及应用
WO2022166725A1 (zh) * 2021-02-08 2022-08-11 南京明德新药研发有限公司 5，6-二氢噻吩并[3，4-h]喹唑啉类化合物
CN113527310B (zh) * 2021-07-30 2022-09-23 上海市肺科医院 用于减轻自身免疫性疾病患者不良炎性反应的小分子化合物及其应用
WO2023104178A1 (zh) * 2021-12-10 2023-06-15 山东绿叶制药有限公司 蛋白激酶抑制剂及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2119975A (en) * 1936-08-26 1938-06-07 Beatrice S Nazel Fluid pressure hammer
JP3907220B2 (ja) * 1994-06-30 2007-04-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 複素環含有化合物
DK0831829T3 (da) 1995-06-07 2003-12-15 Pfizer Heterocykliske, ringkondenserede pyrimidinderivater
US6057329A (en) 1996-12-23 2000-05-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
EA005373B1 (ru) 1999-08-12 2005-02-24 Фармация Италия С.П.А. Производные 3(5)-аминопиразола, способ их получения и их применение в качестве противоопухолевых средств
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
HU229824B1 (en) 2000-08-10 2014-08-28 Pfizer Italia Srl Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
ATE385498T1 (de) * 2000-08-11 2008-02-15 Boehringer Ingelheim Pharma Heterozyklische verbindungen als inhibitoren von tyrosin-kinasen
US20040019046A1 (en) 2000-11-27 2004-01-29 Paolo Pevarello Phenylacetamido-pyrazole derivatives and their use as antitumor agents
JP2004519486A (ja) 2001-01-26 2004-07-02 フアルマシア・イタリア・エツセ・ピー・アー クロマン誘導体、その製造方法及びその抗腫瘍剤としての使用
US20030100594A1 (en) 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
CA2456939A1 (en) * 2001-08-10 2003-02-20 Pharmacia Corporation Carbonic anhydrase inhibitors
JP4542338B2 (ja) 2001-09-26 2010-09-15 ファイザー イタリア ソシエタ ア レスポンサビリタ リミタータ キナーゼ阻害因子として活性なアミノインダゾール誘導体、それらの製造方法及びそれらを含有する医薬組成物
CA2476665A1 (en) * 2002-02-19 2003-08-28 Pharmacia Corporation Tricyclic pyrazole derivatives for the treatment of inflammation
EA010904B1 (ru) 2003-05-22 2008-12-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
HUE024105T2 (hu) * 2006-12-21 2016-02-29 Nerviano Medical Sciences Srl Szubsztituált pirazolo-kinazolin származékok, eljárás azok elõállítására és kináz inhibitorként történõ alkalmazásuk

Also Published As

Publication number Publication date
BR122019010200B1 (pt) 2020-12-15
IS2939B (is) 2016-03-15
US20070185143A1 (en) 2007-08-09
US20150158876A1 (en) 2015-06-11
MXPA05012573A (es) 2006-02-22
GEP20094664B (en) 2009-04-10
AP2005003452A0 (en) 2005-12-31
AU2004240772A1 (en) 2004-12-02
MY142019A (en) 2010-08-16
OA13170A (en) 2006-12-13
BR122019010200B8 (pt) 2021-07-27
US8981089B2 (en) 2015-03-17
US8541429B2 (en) 2013-09-24
TNSN05298A1 (fr) 2007-07-10
CA2526578C (en) 2012-01-24
ES2436524T3 (es) 2014-01-02
RS20050944A (en) 2008-06-05
US20170190714A1 (en) 2017-07-06
MEP25908A (en) 2010-06-10
NZ543661A (en) 2009-05-31
ME00142B (me) 2010-10-10
NO20055496D0 (no) 2005-11-21
PT1636236E (pt) 2013-12-16
SI1636236T1 (sl) 2014-01-31
AU2004240772B2 (en) 2011-04-28
US9637497B2 (en) 2017-05-02
CN102079746A (zh) 2011-06-01
CN1826343A (zh) 2006-08-30
KR101084871B1 (ko) 2011-11-21
ECSP056194A (es) 2006-04-19
AR102722A2 (es) 2017-03-22
CO5721006A2 (es) 2007-01-31
NO334992B1 (no) 2014-08-18
US9464090B2 (en) 2016-10-11
EP1636236A1 (en) 2006-03-22
NO20055496L (no) 2006-02-14
IS8132A (is) 2005-11-18
KR20060015294A (ko) 2006-02-16
HRP20050967A2 (en) 2007-05-31
US20170050972A1 (en) 2017-02-23
AP2064A (en) 2009-10-30
US10280176B2 (en) 2019-05-07
ZA200509486B (en) 2008-09-25
RS52899B (en) 2014-02-28
TW200505924A (en) 2005-02-16
TWI349672B (en) 2011-10-01
EA010904B1 (ru) 2008-12-30
EP1636236B1 (en) 2013-10-09
HRP20050967B8 (hr) 2014-04-25
IL172046A (en) 2017-03-30
US20210300935A1 (en) 2021-09-30
CR8102A (es) 2006-08-09
AR044543A1 (es) 2005-09-21
CY1114708T1 (el) 2016-10-05
EA200501849A1 (ru) 2006-06-30
PL1636236T3 (pl) 2014-02-28
DK1636236T3 (da) 2013-12-09
BRPI0410563A (pt) 2006-06-20
US7482354B2 (en) 2009-01-27
US20090124605A1 (en) 2009-05-14
US20190194214A1 (en) 2019-06-27
UA80763C2 (en) 2007-10-25
US20130338148A1 (en) 2013-12-19
JP5043432B2 (ja) 2012-10-10
HRP20050967B1 (hr) 2014-03-28
CA2526578A1 (en) 2004-12-02
JP2007502851A (ja) 2007-02-15
BRPI0410563B1 (pt) 2020-12-01
WO2004104007A1 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
BRPI0410563B8 (pt) compostos de pirazol-quinazolina, seus processos de preparação e composições farmacêuticas
BRPI0411863A (pt) derivados de pirazolil-indol como inibidores de cinase, processo para seu preparo e composições farmacêuticas compreendendo os mesmos
BR0315988A (pt) Derivados de diidropirimido[4,5-d]pirimidinona substituìda por amino, sua produção e uso como agentes farmacêuticos
BRPI0411868B8 (pt) derivados de pirrol[3,4-c]pirazol ativos como inibidores de cinase
BRPI0606313A2 (pt) derivados de 4-(1h-indol-3-il)-pirimidin-2-ilamina, processo para sua preparação e seu uso em terapia
DE602004017194D1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
ATE514699T1 (de) Substituierte pyrrolopyrazolderivate als kinaseinhibitoren
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
BRPI0507375A (pt) derivados de 1h-tieno[2,3-c]pirazol úteis como inibidores de quinase
BRPI0517634A (pt) derivado de tiazol ou um derivado farmaceuticamente aceitável do mesmo, processo para a preparação de um composto, composição farmacêutica, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
HK1136292A1 (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
BRPI0407834A (pt) composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase
BRPI0416801A (pt) derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
BR0312722A (pt) Derivados de pirazol heterobicìclico como inibidores de qinase
BRPI0512986A (pt) novos derivados de hidantoìna
BRPI0413438A (pt) derivados de pirimidilpirrol ativos como inibidores de cinase
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
BRPI0408486A (pt) derivados de biciclopirazol ativos como inibidores da cinase, processo para a sua preparação e composições farmacêuticas compreendendo-os
UA102219C2 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы
BRPI0508706A (pt) derivados de dicloro-fenil-pirido[2,3-d]pirimidina inusitados, sua fabricação e uso como agentes farmacêuticos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/04/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF